Overall survival, leukemia-free survival higher for patients assigned to allogeneic HCT versus those with no donor<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Dec. 8, 2020 (HealthDay News) — Among older patients with myelodysplastic syndrome (MDS), survival rates are better for those undergoing allogeneic hematopoietic cell transplantation (HCT), according to a study presented at the annual meeting of the American Society of Hematology, held virtually from Dec. 5 to 8.<\/em><\/p>\n Ryotaro Nakamura, M.D., from the City of Hope in Duarte, California, and colleagues conducted a biologic assignment trial in older individuals (aged 50 to 75 years) with high-risk MDS who were candidates for reduced-intensity conditioning allogeneic HCT to examine the benefit of HCT versus non-HCT therapy. Based on human leukocyte antigen typing of eligible family members and a search of unrelated donor registries, participants were assigned to the donor or no donor arm. The primary analysis compared three-year overall survival (OS) between 384 subjects (260 in the donor arm and 124 in the no donor arm).<\/p>\n The researchers found that the adjusted OS at three years from study enrollment was 47.9 and 26.6 percent in the donor and no donor arms, respectively, in the intent-to-treat analysis. No effect was seen on outcome in sensitivity analysis excluding subjects assigned to the no donor arm who died or withdrew prior to the end of the 90-day search window (48.0 versus 28.1 percent). Compared with the no donor arm, the donor arm had greater leukemia-free survival at three years (35.8 versus 20.6 percent), with no difference seen in the sensitivity analysis.<\/p>\n “It is important to refer these patients early so that the transplant center can work on finding an optimal donor right from the get-go,” a coauthor said in a statement.<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n Press Release<\/a><\/p>\n Abstract<\/a><\/p>\n